Alex Dale, Author at Labiotech.eu

About

A former journalist intern at Labiotech, Alex now works as a copywriter in healthcare advertising. When he’s not writing, he enjoys playing sports and long-distance cycling.

Articles by Alex Dale

News and Trends 8 Jan 2018

And We’re Off! First Patient Dosed in this Spanish Biotech’s Rare Disease Trial

Minoryx Therapeutics has dosed the first patient in its Phase II/III trial for patients with adrenomyeloneuropathy, a condition that affects 1 in 17,000 newborns worldwide. Minoryx Therapeutics focuses on the development of new drugs for orphan diseases like adrenomyeloneuropathy. The first two patients in ADVANCE, a Phase II/III clinical trial of MIN-102, have started their treatment. The trial, […]

January 8, 2018 - 3 minutesmins - By Alex Dale

News and Trends 8 Jan 2018

This British Liquid Biopsy Could Save Us $5000 per Prostate Cancer Patient

ANGLE’s liquid biopsy technology measures the expression of an important prostate cancer biomarker, helping to identify the best treatment for different groups of patients. ANGLE is a world leader in the development of liquid biopsies – a technique for the early detection of cancer, which doesn’t require invasive tissue samples. The biotech published results in […]

January 8, 2018 - 3 minutesmins - By Alex Dale

News and Trends 8 Jan 2018

This Skin Patch Could Slow the Rate of Antibiotic Resistance

Researchers have developed a skin patch that delivers drugs directly into the blood, avoiding the gut which is a breeding ground for antibiotic resistance. Researchers at Queen’s University Belfast are developing a skin patch to deliver drugs through the skin and directly into the bloodstream via thousands of ‘microneedles’. The technology is being tested as a […]

January 8, 2018 - 3 minutesmins - By Alex Dale

More News! 4 Jan 2018

Belgian Biotech Hits ‘Fast Forward’ on Multiple Sclerosis Therapies

Rewind Therapeutics has received a boost in the development of its multiple sclerosis therapies, raising a €15.2M Series A fundraising round. Rewind Therapeutics is a young Belgian biotech, which was co-founded by CD3 and Axxam, based in Leuven, Belgium, and Milan, Italy, respectively. Today, the biotech announced that it has completed a €15.2M Series A financing […]

January 4, 2018 - 2 minutesmins - By Alex Dale

News and Trends 4 Jan 2018

Boehringer Ingelheim Doubles its Venture Fund for Exciting Biotech

Boehringer Ingelheim has committed to continue helping young companies grow by doubling the size of its venture fund to €250M, which will allow it to expand its focus. Boehringer Ingelheim is a big pharma hoping to drive the development of new and effective medicines. Today, the company announced that it has more than doubled the size of […]

January 4, 2018 - 2 minutesmins - By Alex Dale

News and Trends 4 Jan 2018

Enterome Brings in a €32M Series D for its Microbiome-Based Therapies

Enterome will use the money to progress two of its leading microbiome programs for the treatment of Crohn’s disease and an aggressive form of brain cancer. Enterome is a pioneer in the exciting field of microbiome-based therapies for diseases like inflammatory bowel diseases and cancer. This morning, the company has announced that it has raised €32M in […]

January 4, 2018 - 3 minutesmins - By Alex Dale

News and Trends 4 Jan 2018

Swedish Biotech Pockets $6M as its Cancer Antibody Heads for the Clinic

Alligator Bioscience will receive milestone payments from its partner, Janssen, following the announcement of a combination trial using its cancer antibody. Alligator develops antibodies to fight cancer, and today it has announced that it will receive $6M (€5M) in milestone payments from Janssen. This was triggered by the announcement of a combination trial for its candidate, ADC-1013, which […]

January 4, 2018 - 2 minutesmins - By Alex Dale

In Depth 4 Jan 2018

A Crash Course in the Basics of Finance in Biotechnology

Getting your head around intricate biotech research and technology can be difficult enough, without having to contend with financial figures and jargon. With news coming out thick and fast, you might be switching from the first market approval of a CAR-T therapy to the latest strategy to protect crops from pests to a new anti-Parkinson’s […]

January 4, 2018 - 5 minutesmins - By Alex Dale

News and Trends 3 Jan 2018

Swiss Biotech Gets $339M to Boost the Development of Drug Addiction Therapies

Addex Therapeutics, which develops drugs for neurological disorders, has signed an agreement with Indivior to propel its drug addiction pipeline forward. Addex, a top biotech from Geneva, develops small molecules for the treatment of neurological disorders. Today, the company has announced that a collaboration worth up to $339M (€282M) has been signed with Indivior that will focus on progressing […]

January 3, 2018 - 3 minutesmins - By Alex Dale

News and Trends 3 Jan 2018

What Are Clinical Trials and Why Do We Do Them?

If you’ve read any of our articles, you’ll have no doubt heard us banging on about clinical trials, Phase I, Phase II, market approval… But what does this all mean? We’ve put together a quick guide to help you through these crucial stages of drug development. To reach a clinical trial, the drug will have […]

January 3, 2018 - 6 minutesmins - By Alex Dale

In Depth 2 Jan 2018

The Labiotech Dictionary of Important Biotech Terms

Biotech is constantly changing, which means that new key terms are popping up all the time. We’ve put together The Labiotech Dictionary of Important Biotech Terms to bring you up to speed. New and exciting findings come thick and fast in the biotech industry, making it hard to keep up with this ever-changing field. Whether […]

January 2, 2018 - 14 minutesmins - By Alex Dale

News and Trends 20 Dec 2017

Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies

Idorsia and Roche have agreed on a research collaboration, with the big pharma getting exclusive rights to develop and license resultant cancer immunotherapy drugs. Idorsia was formed out of J&J’s acquisition of Actelion for €27.9B at the beginning of the year. The spin out, led by Jean-Paul and Martine Clozel, kept hold of Actelion’s drug discovery and early […]

December 20, 2017 - 2 minutesmins - By Alex Dale

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Alex Dale

About

Articles by Alex Dale

And We’re Off! First Patient Dosed in this Spanish Biotech’s Rare Disease Trial

This British Liquid Biopsy Could Save Us $5000 per Prostate Cancer Patient

This Skin Patch Could Slow the Rate of Antibiotic Resistance

Belgian Biotech Hits ‘Fast Forward’ on Multiple Sclerosis Therapies

Boehringer Ingelheim Doubles its Venture Fund for Exciting Biotech

Enterome Brings in a €32M Series D for its Microbiome-Based Therapies

Swedish Biotech Pockets $6M as its Cancer Antibody Heads for the Clinic

A Crash Course in the Basics of Finance in Biotechnology

Swiss Biotech Gets $339M to Boost the Development of Drug Addiction Therapies

What Are Clinical Trials and Why Do We Do Them?

The Labiotech Dictionary of Important Biotech Terms

Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Alex Dale

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!